Characterization of the Ontogeny of Hepatic UDP-Glucuronosyltransferase Enzymes Based on Glucuronidation Activity Measured in Human Liver Microsomes
- PMID: 31502688
- DOI: 10.1002/jcph.1493
Characterization of the Ontogeny of Hepatic UDP-Glucuronosyltransferase Enzymes Based on Glucuronidation Activity Measured in Human Liver Microsomes
Abstract
An understanding of the postnatal development of hepatic UDP-glucuronosyltransferase (UGT) enzymes is required for accurate prediction of the age-dependent changes in pharmacokinetics of many drugs used in children. However, the maturation rate of hepatic UGT isoforms remains a major knowledge gap. This study aimed to establish the age-associated changes in glucuronidation activity of 10 major hepatic UGT isoforms in humans, namely, UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B4, UGT2B7, UGT2B10, UGT2B15, and UGT2B17. Human liver microsomes from pediatric and adult donors were incubated under optimized incubation conditions to assess the activity rates of hepatic UGT isoforms using a panel of 19 in vitro UGT probe substrates and clinically used drugs. Statistically strong correlations of glucuronidation activities allowed the ontogeny of UGT1A1, UGT1A4, UGT2B7, UGT2B10, and UGT2B15 to be established using multiple selective UGT substrates and matched human liver microsome samples. The postnatal development of hepatic UGTs is isoform-dependent using either individual or cross-correlated selective isoform substrates. Maximal adult activity was reached at different times ranging from within a month (UGT1A1, UGT2B4, UGT2B7, UGT2B10, and UGT2B15), during infancy (UGT1A3, UGT1A4, and UGT1A9), to adolescence (UGT1A6 and UGT2B17). This study provides an extensive characterization of the postnatal ontogeny profiles of hepatic UGT enzymes that are instrumental for predicting drug disposition via in vitro-in vivo extrapolation algorithms and verifying pharmacokinetic predictions against in vivo observations via pediatric physiologically based pharmacokinetic modeling in pediatric patients.
Keywords: UDP-glucuronosyltransferase; cross-correlated selective isoform substrates; human liver microsome; ontogeny.
© 2019, The American College of Clinical Pharmacology.
Similar articles
-
Optimization of Experimental Conditions of Automated Glucuronidation Assays in Human Liver Microsomes Using a Cocktail Approach and Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry.Drug Metab Dispos. 2019 Feb;47(2):124-134. doi: 10.1124/dmd.118.084301. Epub 2018 Nov 26. Drug Metab Dispos. 2019. PMID: 30478159
-
Human UDP-glucuronosyltransferase isoforms involved in bisphenol A glucuronidation.Chemosphere. 2008 Dec;74(1):33-6. doi: 10.1016/j.chemosphere.2008.09.053. Epub 2008 Nov 5. Chemosphere. 2008. PMID: 18990428
-
Developmental aspects of human hepatic drug glucuronidation in young children and adults.Gut. 2002 Feb;50(2):259-65. doi: 10.1136/gut.50.2.259. Gut. 2002. PMID: 11788570 Free PMC article.
-
Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases.Methods Enzymol. 2005;400:104-16. doi: 10.1016/S0076-6879(05)00007-8. Methods Enzymol. 2005. PMID: 16399346 Review.
-
Prediction of hepatic and intestinal glucuronidation using in vitro-in vivo extrapolation.Drug Metab Pharmacokinet. 2015 Feb;30(1):21-9. doi: 10.1016/j.dmpk.2014.10.001. Epub 2014 Oct 13. Drug Metab Pharmacokinet. 2015. PMID: 25760528 Review.
Cited by
-
Physiologically Based Pharmacokinetics Modeling in the Neonatal Population-Current Advances, Challenges, and Opportunities.Pharmaceutics. 2023 Nov 3;15(11):2579. doi: 10.3390/pharmaceutics15112579. Pharmaceutics. 2023. PMID: 38004559 Free PMC article. Review.
-
Verifying in vitro-determined enzyme contributions to cannabidiol clearance for exposure predictions in human through physiologically-based pharmacokinetic modeling.CPT Pharmacometrics Syst Pharmacol. 2023 Mar;12(3):320-332. doi: 10.1002/psp4.12908. Epub 2023 Jan 8. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 36540909 Free PMC article.
-
Pharmacokinetics and Pharmacodynamics of Posaconazole.Drugs. 2020 May;80(7):671-695. doi: 10.1007/s40265-020-01306-y. Drugs. 2020. PMID: 32323222 Free PMC article. Review.
-
Current opinion: antiretrovirals during pregnancy and breastfeeding.Curr Opin HIV AIDS. 2024 Nov 1;19(6):305-315. doi: 10.1097/COH.0000000000000884. Epub 2024 Sep 20. Curr Opin HIV AIDS. 2024. PMID: 39514785 Free PMC article. Review.
-
Physiologically-Based Pharmacokinetics and Empirical Pharmacodynamic Modeling for Pediatric Henagliflozin Dosing: Clinical Insights for Chinese Patients.Pediatr Diabetes. 2025 Aug 7;2025:8857248. doi: 10.1155/pedi/8857248. eCollection 2025. Pediatr Diabetes. 2025. PMID: 40822299 Free PMC article.
References
-
- Rowland A, Miners JO, Mackenzie PI. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol. 2013;45(6):1121-1132.
-
- Owens IS, Basu NK, Banerjee R. UDP-Glucuronosyltransferases: gene structures of UGT1 and UGT2 families. Methods Enzymol. 2005;400:1-22.
-
- Meech R, Mubarokah N, Shivasami A, et al. A novel function for UDP glycosyltransferase 8: galactosidation of bile acids. Mol Pharmacol. 2015;87(3):442-450.
-
- Meech R, Rogers A, Zhuang L, Lewis BC, Miners JO, Mackenzie PI. Identification of residues that confer sugar selectivity to UDP-glycosyltransferase 3A (UGT3A) enzymes. J Biol Chem. 2012;287(29):24122-24130.
-
- Badée J, Fowler S, de Wildt SN, Collier AC, Schmidt S, Parrott N. The ontogeny of UDP-glucuronosyltransferase enzymes, recommendations for future profiling studies and application through physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2019;58(2):189-211.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous